One-center experience with cyclosporine in refractory nephrotic syndrome in children

Singh, Anup; Tejani, Cena; Tejani, A.
January 1999
Pediatric Nephrology;1999, Vol. 13 Issue 1, p26
Academic Journal
Uncontrolled or refractory nephrotic syndrome (NS), seen in a variety of glomerular disorders, leads to end-stage renal disease (ESRD). This study describes the use and efficacy of cyclosporine (CSA) for the treatment of refractory NS in 83 children seen over a 10-year period. The histological diagnosis leading to the NS was focal segmental glomerulosclerosis (FSGS) in 51% (n=42), IgM nephropathy in 20% (n=17), membranoproliferative glomerulonephritis in 10% (n=8), lupus nephritis in 6% (n=5), human immunodeficiency vires (HIV) nephropathy in 5% (n=4), minimal change disease in 7% (n=6), and membranous nephropathy in 1% (n=l) of patients. During CSA therapy the mean proteinuria of the study population decreased from 5.14 g/24 h (4.80 g/m² per 24 h) to 1.23 g/24 h (0.92 g/m² per 24 h) (P<0.001), the mean serum albumin increased from 2.13 g/dl to 3.53 g/dl (P<0.001), the mean serum cholesterol decreased from 364 mg/dl to 223 mg/dl (P<0.001), and the mean serum creatinine increased from 0.77 mg/dl to 1.2 mg/dl (P<0.01). When analyzed by histological diagnosis, similar significant trends of reduction in proteinuria were seen in all but the lupus group. There was a rise in serum creatinine following the use of CSA in patients with FSGS, lupus nephritis, and HIV nephropathy; however the elevated serum creatinine was only significant in patients with FSGS. At the end of the study period, 20 patients had reached ESRD, of which 11 had FSGS, 5 had lupus nephritis, and 4 were patients with HIV nephropathy. Fifty-four patients were in remission at the end of the study period (48 with proteinuria <100 mg/24 h and 6 with proteinuria <500 mg/24 h). In conclusion, among children with refractory NS, CSA induced a remission in a large proportion. However toxicity, as noted by the rise in serum creatinine, was observed in several patients. Since this toxicity may be drug induced or a natural progression of the disease, careful monitoring and close follow-up are essential.


Related Articles

  • Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Inoue, Yuji; Iijima, Kazumoto; Nakamura, Hajime; Yoshikawa, N. // Pediatric Nephrology;1999, Vol. 13 Issue 1, p33 

    We describe a prospective study of 2-year moderate-dose cyclosporin (CS) treatment in 13 children with steroid-dependent minimal change nephrotic syndrome (MCNS). CS treatment was commenced at 100-150mg/m² per day after remission was attained with prednisolone therapy, was adjusted to a...

  • Quantitative morphometry of renal biopsies prior to cyclosporine in nephrotic syndrome. Smoyer, William E.; Gregory, Melissa J.; Bajwa, Ravinder S.; Johnson, Kent J.; Bunchman, Timothy E. // Pediatric Nephrology;1998, Vol. 12 Issue 9, p737 

    Use of cyclosporine (CsA) in the management of children with steroid-resistant (SRNS) and steroid-dependent (SDNS) nephrotic syndrome has become increasingly popular in recent years. Although most children receive a renal biopsy prior to initiation of CsA, the relationship between initial renal...

  • Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome. Yorgin, P. D.; Krasher, Judy; Al-Uzri, Amira Y. // Pediatric Nephrology;2001, Vol. 16 Issue 3, p245 

    Although much of the interest in pulse methylprednisolone therapy (PMT) has centered around its use in children with focal segmental glomerulosclerosis, PMT has also been shown to be effective in the treatment of other proteinuric renal diseases. We hypothesized that a PMT-based treatment...

  • Long-Term CsA Decreases SDNS in Children.  // Kidney;Jan/Feb99, Vol. 8 Issue 1, p12 

    Presents the findings of a study which reported on a single-center experience with long-term moderate-dose cyclosporine (CsA) treatment of children with steroid-dependent nephrotic syndrome (SDNS) or steroid-resistant NS (SRNS). Conclusion that long-term use of CsA result in a decrease in the...

  • The use of steroid-sparing agents in steroid-sensitive nephrotic syndrome. Abeyagunawardena, Asiri S.; Dillon, Michael.J.; Rees, Lesley; Hoff, William Vant't; Trompeter, Richard S. // Pediatric Nephrology;Sep2003, Vol. 18 Issue 9, p919 

    Childhood nephrotic syndrome (NS) is frequently characterized by a relapsing course. There is no uniform agreement about the precise stage at which a steroid-sparing agent should be introduced to control the disease. In order to evaluate the treatment strategies and outcome of steroid-sensitive...

  • Interventions for steroid-resistant nephrotic syndrome: a systematic review. Habashy, Doaa.; Hodson, Elisabeth M.; Craig, Jonathan C. // Pediatric Nephrology;Sep2003, Vol. 18 Issue 9, p906 

    In a systematic review and meta-analysis of randomized controlled trials (RCT), we aimed to evaluate the benefits and harms of all interventions for children with steroid-resistant nephrotic syndrome (SRNS). Nine RCTs involving 225 children were included. Cyclosporin when compared with placebo...

  • Secondary resistance to cyclosporin A in children with nephrotic syndrome. Sairam, Vellore K.; Kalia, Alok; Rajaraman, Srinivasan; Travis, Luther B. // Pediatric Nephrology;Oct2002, Vol. 17 Issue 10, p842 

    We investigated the phenomenon of secondary resistance to cyclosporin (CsA) in children with steroid dependent (SD) or steroid resistant (SR) nephrotic syndrome. Secondary resistance was defined as an initial response to CsA with relapse on withdrawal of therapy and absent or diminished response...

  • Cyclosporin-related nephrotoxicity in children with nephrotic syndrome. Ganesan, V.; Milford, D. V.; Taylor, C. M.; Hulton, S. A.; Parvaresh, S.; Ramani, P. // Pediatric Nephrology;Mar2002, Vol. 17 Issue 3, p225 

    Comments on a study about the clinical and pathological effects of cyclosporin A in children with nephrotic syndrome. Information on renal biopsies; Conditions sought in the glomeruli; Comparison of glomerular filtration rates.

  • 39th and 40th Annual Meeting of the Japanese Society for Pediatric Nephrology, 2004 and 2005.  // Pediatric Nephrology;Sep2006, Vol. 21 Issue 9, p1335 

    The article presents abstracts of medical research presented at the 39th and 40th Annual Meetings of the Japanese Society for Pediatric Nephrology in 2004 and 2005. They include: "Therapeutic effects of mycophenolate mofetil (MMF) on multidrug-resistant, intractable nephrotic syndrome," "Segment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics